{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T16:05:52Z","timestamp":1792857952548,"version":"4.5.0"},"reference-count":36,"publisher":"Georg Thieme Verlag KG","issue":"02","funder":[{"name":"China Postdoctoral Science Foundation","award":["2020M683128"],"award-info":[{"award-number":["2020M683128"]}],"id":[{"id":"https:\/\/ror.org\/0426zh255","id-type":"ROR","asserted-by":"crossref"}]},{"name":"The National Natural Science Foundation of China","award":["82100648"],"award-info":[{"award-number":["82100648"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Liver Dis"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:p>Traditional classifications of metabolic dysfunction-associated steatotic liver disease (MASLD) based on histology or biochemical traits are insufficient to capture its complexity, and clinical strategies rely on generalized treatment approaches that may not target to patient heterogeneity. As MASLD is a highly prevalent and heterogeneous condition with diverse clinical trajectories and outcomes ranged from liver-related complications to multiple extrahepatic complications, emerging approaches integrating clinical features, genotypes, multi-omics (microbiota, metabolomics, proteomics, and related post-translational modifications), machine learning\u2013based clustering, and molecular profiling have enabled more refined disease subtyping. This review underscores novel subtyping frameworks of MASLD beyond traditional methods, focusing on their clinical relevance and translational potential. We further identify gaps in standardization across studies, the limitations of existing models, and highlight the need for integrative, longitudinal approaches to improve precision medicine. In conclusion, clustering subtypes might facilitate risk stratification and guide personalized therapeutic strategies to prioritize these expensive treatments to the right phenotype of MASLD.<\/jats:p>","DOI":"10.1055\/a-2926-5401","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T23:42:51Z","timestamp":1785368571000},"page":"196-213","source":"Crossref","is-referenced-by-count":2,"title":["Toward Precision Medicine in MASLD: Evolution of Disease Subtyping"],"prefix":"10.1055","volume":"46","author":[{"given":"Ting","family":"Feng","sequence":"first","affiliation":[{"name":"The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangdong, People's Republic of China","place":["Guangzhou"],"department":["Department of Gastroenterology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaming","family":"Li","sequence":"first","affiliation":[{"name":"The Fifth People's Hospital of Shunde District, Guangdong, People's Republic of China","place":["Foshan"],"department":["Department of Gastroenterology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyi","family":"Ma","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Sun Yat-sen University, Guangdong, People's Republic of China","place":["Guangzhou"],"department":["Department of Geriatrics"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3163-4164","authenticated-orcid":false,"given":"Junzhao","family":"Ye","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Sun Yat-sen University, Guangdong, People's Republic of China","place":["Guangzhou"],"department":["Department of Gastroenterology"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"issue":"06","key":"ref1","doi-asserted-by":"crossref","first-page":"103043","DOI":"10.1016\/j.arcmed.2024.103043","article-title":"Global prevalence of nonalcoholic fatty liver disease: an updated review meta-analysis comprising a population of 78 million from 38 countries","volume":"55","author":"E Amini-Salehi","year":"2024","journal-title":"Arch Med Res"},{"issue":"13","key":"ref2","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1016\/j.cgh.2025.02.006","article-title":"High global prevalence of steatotic liver disease and associated subtypes: a meta-analysis","volume":"23","author":"G JK Ho","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"ref3","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/S2468-1253(24)00193-6","article-title":"Natural history and progression of metabolic dysfunction-associated steatotic liver disease","volume":"9","author":"H Hagstr\u00f6m","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref4","first-page":"20","article-title":"Metabolic benefits of changing sedentary lifestyles in nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials","volume":"13","author":"Q Ma","year":"2022","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"06","key":"ref5","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1111\/liv.15571","article-title":"Hepatocytic ballooning in non-alcoholic steatohepatitis: dilemmas and future directions","volume":"43","author":"Y Y Li","year":"2023","journal-title":"Liver Int"},{"issue":"06","key":"ref6","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/apt.17635","article-title":"AutoFibroNet: a deep learning and multi-photon microscopy-derived automated network for liver fibrosis quantification in MAFLD","volume":"58","author":"H Zhan","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"issue":"09","key":"ref7","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1111\/j.1572-0241.1999.01377.x","article-title":"Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions","volume":"94","author":"E M Brunt","year":"1999","journal-title":"Am J Gastroenterol"},{"issue":"02","key":"ref8","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.hepres.2005.09.006","article-title":"Pathology of nonalcoholic steatohepatitis","volume":"33","author":"E M Brunt","year":"2005","journal-title":"Hepatol Res"},{"issue":"06","key":"ref9","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"D E Kleiner","year":"2005","journal-title":"Hepatology"},{"issue":"05","key":"ref10","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/hep.25889","article-title":"Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients","volume":"56","author":"P Bedossa","year":"2012","journal-title":"Hepatology"},{"issue":"14","key":"ref11","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1097\/CM9.0000000000002277","article-title":"Estimating global prevalence, incidence, and outcomes of non-alcoholic fatty liver disease from 2000 to 2021: systematic review and meta-analysis","volume":"135","author":"J Liu","year":"2022","journal-title":"Chin Med J (Engl)"},{"issue":"11","key":"ref12","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S2468-1253(21)00308-3","article-title":"Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis","volume":"6","author":"A Mantovani","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"03","key":"ref13","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/apt.18451","article-title":"Meta-analysis: global prevalence and mortality of cirrhosis in metabolic dysfunction-associated steatotic liver disease","volume":"61","author":"S Owrangi","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"issue":"07","key":"ref14","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"M Eslam","year":"2020","journal-title":"Gastroenterology"},{"issue":"03","key":"ref15","doi-asserted-by":"crossref","first-page":"e16133","DOI":"10.1111\/liv.16133","article-title":"Impact of PNPLA3 I148M on clinical outcomes in patients with MASLD","volume":"45","author":"S Petta","year":"2025","journal-title":"Liver Int"},{"issue":"01","key":"ref16","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3350\/cmh.2024.0631","article-title":"Long-term outcomes and risk modifiers of metabolic dysfunction-associated steatotic liver disease between lean and non-lean populations","volume":"31","author":"P Danpanichkul","year":"2025","journal-title":"Clin Mol Hepatol"},{"issue":"06","key":"ref17","doi-asserted-by":"crossref","first-page":"102569","DOI":"10.1016\/j.cpcardiol.2024.102569","article-title":"Cardiovascular morbidity and mortality in lean vs. non-lean MASLD: a comprehensive meta-analysis","volume":"49","author":"N Nso","year":"2024","journal-title":"Curr Probl Cardiol"},{"issue":"09","key":"ref18","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S2468-1253(23)00157-7","article-title":"Type 2 diabetes, hepatic decompensation, and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: an individual participant-level data meta-analysis","volume":"8","author":"D Q Huang","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"07","key":"ref19","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s00535-024-02098-8","article-title":"The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosis","volume":"59","author":"J Ampuero","year":"2024","journal-title":"J Gastroenterol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"155294","DOI":"10.1016\/j.metabol.2022.155294","article-title":"Novel metabolic classification for extrahepatic complication of metabolic associated fatty liver disease: a data-driven cluster analysis with international validation","volume":"136","author":"J Ye","year":"2022","journal-title":"Metabolism"},{"issue":"01","key":"ref21","doi-asserted-by":"crossref","first-page":"e0016","DOI":"10.1097\/HC9.0000000000000016","article-title":"Novel metabolic phenotypes for extrahepatic complication of nonalcoholic fatty liver disease","volume":"7","author":"J Yi","year":"2023","journal-title":"Hepatol Commun"},{"issue":"11","key":"ref22","doi-asserted-by":"crossref","first-page":"e067203","DOI":"10.1136\/bmjopen-2022-067203","article-title":"Phenotypes of non-alcoholic fatty liver disease (NAFLD) and all-cause mortality: unsupervised machine learning analysis of NHANES III","volume":"12","author":"R M Carrillo-Larco","year":"2022","journal-title":"BMJ Open"},{"issue":"03","key":"ref23","doi-asserted-by":"crossref","first-page":"103797","DOI":"10.1016\/j.numecd.2024.103797","article-title":"Cardiometabolic phenotype linked to fibrosis and mortality in metabolic dysfunction-associated steatotic liver disease","volume":"35","author":"R Dong","year":"2025","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"06","key":"ref24","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.jhep.2025.02.032","article-title":"Subtypes of MASLD confer distinct clinical trajectories","volume":"82","author":"P K Luukkonen","year":"2025","journal-title":"J Hepatol"},{"issue":"12","key":"ref25","doi-asserted-by":"crossref","first-page":"3624","DOI":"10.1038\/s41591-024-03283-1","article-title":"Data-driven cluster analysis identifies distinct types of metabolic dysfunction-associated steatotic liver disease","volume":"30","author":"V Raverdy","year":"2024","journal-title":"Nat Med"},{"issue":"01","key":"ref26","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12933-026-03180-6","article-title":"Multi-omics uncovers the pleiotropic genetic mechanisms linking MASLD and cardiometabolic syndromes","volume":"25","author":"K Yin","year":"2026","journal-title":"Cardiovasc Diabetol"},{"issue":"12","key":"ref27","doi-asserted-by":"crossref","first-page":"3614","DOI":"10.1038\/s41591-024-03284-0","article-title":"Partitioned polygenic risk scores identify distinct types of metabolic dysfunction-associated steatotic liver disease","volume":"30","author":"O Jamialahmadi","year":"2024","journal-title":"Nat Med"},{"issue":"01","key":"ref28","first-page":"101645","article-title":"Validation of a data-driven clustering model for MASLD: evidence from three large-scale Asian cohorts","volume":"8","author":"X D Zhou","year":"2025","journal-title":"JHEP Rep Innov Hepatol"},{"issue":"04","key":"ref29","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.3390\/ijms26041589","article-title":"Unraveling metabolic dysfunction-associated steatotic liver disease through the use of omics technologies","volume":"26","author":"M V Bourganou","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"04","key":"ref30","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/hep.32427","article-title":"Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles","volume":"76","author":"I Mart\u00ednez-Arranz","year":"2022","journal-title":"Hepatology"},{"issue":"01","key":"ref31","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s12944-023-01878-0","article-title":"Identification and immunological characterization of lipid metabolism-related molecular clusters in nonalcoholic fatty liver disease","volume":"22","author":"J Liu","year":"2023","journal-title":"Lipids Health Dis"},{"issue":"01","key":"ref32","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1186\/s12967-023-04300-6","article-title":"Identifying a distinct fibrosis subset of NAFLD via molecular profiling and the involvement of profibrotic macrophages","volume":"21","author":"W He","year":"2023","journal-title":"J Transl Med"},{"issue":"772","key":"ref33","doi-asserted-by":"crossref","first-page":"eadh9940","DOI":"10.1126\/scitranslmed.adh9940","article-title":"Integrative multiomic analysis identifies distinct molecular subtypes of NAFLD in a Chinese population","volume":"16","author":"J Ding","year":"2024","journal-title":"Sci Transl Med"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"857892","DOI":"10.3389\/fimmu.2022.857892","article-title":"Identification of the non-alcoholic fatty liver disease molecular subtypes associated with clinical and immunological features via bioinformatics methods","volume":"13","author":"Z Liu","year":"2022","journal-title":"Front Immunol"},{"issue":"07","key":"ref35","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1038\/s42255-026-01543-7","article-title":"A data-driven framework reconstructs the molecular continuum of human MASLD progression","volume":"8","author":"I Kamzolas","year":"2026","journal-title":"Nat Metab"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000001811","article-title":"Decoding fibrosis: transcriptomic and clinical insights via AI-derived collagen deposition phenotypes in MASLD","author":"M Wojciechowska","year":"2026","journal-title":"Hepatology"}],"container-title":["Seminars in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2926-5401.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:40:17Z","timestamp":1790894417000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2926-5401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":36,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2026,10,1]]},"published-print":{"date-parts":[[2026,6]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2926-5401","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0272-8087","1098-8971"],"issn-type":[{"value":"0272-8087","type":"print"},{"value":"1098-8971","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7,29]]},"published":{"date-parts":[[2026,6]]}}}